Endocrine · 2020
Thyroid function and lipid profile in euthyroid adults: the TCLSIH cohort study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gu Yeqing, Meng Ge, Zhang Qing, Liu Li, Wu Hongmei, Zhang Shunming, Wang Yawen, Zhang Tingjing, Wang Xuena, Cao Xingqi, Li Huiping, Liu Yunyun, Li Xiaoyue, Wang Xiaohe, Sun Shaomei, Zhou Ming, Jia Qiyu, Song Kun, Niu Kaijun
Аннотация
PURPOSE: Thyroid hormones (THs) have multiple effects on lipid synthesis, mobilization, and degradation, suggesting that THs may affect the development of dyslipidemia. However, prospective studies on the association between serum THs levels and incident dyslipidemia in euthyroid subjects are limited. Therefore, we conducted a cohort study (~5-year follow-up period, median: 3.0 years) to explore whether THs can affect incident dyslipidemia in a general euthyroid population aged 18 years old and over.
METHODS: Dyslipidemia is characterized by elevated total cholesterol (TC), triglyceride (TG), or low-density lipoprotein cholesterol (LDL-C), or reduced high-density lipoprotein cholesterol (HDL-C). Serum free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were determined by chemiluminescence immunoassay. Multivariable Cox proportional hazards regression models were used to assess the association between baseline FT3, FT4, TSH, and the risk of various dyslipidemias.
RESULTS: During follow-up period, the incidence of elevated TC, TG, LDL-C, and reduced HDL-C was 29.3%, 20.7%, 24.8%, and 19.5%, respectively. After adjustment for multiple confounders, we found that per unit increase in FT3 concentrations were associated with decreased incidence of elevated TC and LDL-C, and the hazard ratios (95% confidence interval) were 0.87 (0.79-0.97) (P < 0.01) and 0.897 (0.808-0.995) (P = 0.04), respectively. We also found a weak positive association between TSH and incidence of reduced HDL-C (P = 0.02). However, we found no association between FT4 and incident dyslipidemia.
CONCLUSIONS: Our results demonstrated that low FT3 was associated with high dyslipidemia risk, especially for elevated TC and LDL-C, and that TSH had a weak positive effect on incidence of reduced HDL-C.
METHODS: Dyslipidemia is characterized by elevated total cholesterol (TC), triglyceride (TG), or low-density lipoprotein cholesterol (LDL-C), or reduced high-density lipoprotein cholesterol (HDL-C). Serum free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were determined by chemiluminescence immunoassay. Multivariable Cox proportional hazards regression models were used to assess the association between baseline FT3, FT4, TSH, and the risk of various dyslipidemias.
RESULTS: During follow-up period, the incidence of elevated TC, TG, LDL-C, and reduced HDL-C was 29.3%, 20.7%, 24.8%, and 19.5%, respectively. After adjustment for multiple confounders, we found that per unit increase in FT3 concentrations were associated with decreased incidence of elevated TC and LDL-C, and the hazard ratios (95% confidence interval) were 0.87 (0.79-0.97) (P < 0.01) and 0.897 (0.808-0.995) (P = 0.04), respectively. We also found a weak positive association between TSH and incidence of reduced HDL-C (P = 0.02). However, we found no association between FT4 and incident dyslipidemia.
CONCLUSIONS: Our results demonstrated that low FT3 was associated with high dyslipidemia risk, especially for elevated TC and LDL-C, and that TSH had a weak positive effect on incidence of reduced HDL-C.